Spotlight on Surgery

Credits: 1.00 AANA / CME / MOCA
Neuromuscular Blockade Reversal: Navigating the Therapeutic Landscape to Achieve Optimal Patient Outcomes
J. Ross Renew, MD, FASA, FASE
Vindico

Neuromuscular Blockade Reversal: Navigating the Therapeutic Landscape to Achieve Optimal Patient Outcomes

Start

Activity Details

Free CME/MOCA/AANA
1.0 AMA PRA Category 1 Credit(s)™ with ABA MOCA 2.0; AANA Class A CE Credit
Released: 6/30/2021
Expires: 6/29/2022
60 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for the activity is anesthesiologists, surgeons, nurse anesthetists, and other health care professionals involved in the management of patients undergoing anesthesia.

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

  • Review the benefits and limitations of current reversal agents.
  • Examine the best practices for the use of neuromuscular blocking agents, including the value of appropriate monitoring.
  • Assess the most recent evidence regarding the safety and efficacy of current and emerging therapies for the reversal of neuromuscular blocking agents.
  • Evaluate the significance of a multidisciplinary approach to manage surgical patients in need of deep neuromuscular blockade.

Activity Description

The introduction of neuromuscular blockade agents (NMBAs) revolutionized the field of anesthesia. However, termination of the effects of these agents remains elusive, and they still have the potential for significant adverse outcomes. The cholinesterase inhibitor drugs first used to reverse curare have traditionally been used for reversing all NMBAs, but due to the limitations of these agents and the complications of residual neuromuscular block, development of improved reversal agents has been underway. A new class of drugs, selective relaxant binding agents, may overcome the limitations of cholinesterase inhibitors and quickly reverse both shallow and deep levels of aminosteroid neuromuscular block. In this podcast series, expert faculty review the benefits and limitations of current and emerging reversal agents, best practices for monitoring patients undergoing neuromuscular blockade, and the importance of a multidisciplinary approach when managing patients in the surgical setting.

Agenda

Best Practices for Monitoring Neuromuscular Blockade with J. Ross Renew, MD, FASA, FASE, and Anthony L. Kovac, MD
Benefits and Drawbacks of Conventional Reversal Agents with J. Ross Renew, MD, FASA, FASE, and Richard Pence, CRNA, MHA
Current and Emerging NMB Therapies with  J. Ross Renew, MD, FASA, FASE, and Anthony L. Kovac, MD
Significance of a Multidisciplinary Approach for NMBAs with J. Ross Renew, MD, FASA, FASE, and Richard Pence, CRNA, MHA

Activity Chair

J. Ross Renew, MD, FASA, FASE
Assistant Professor of Anesthesiology
Mayo Clinic
Jacksonville, FL

Disclosure: Contracted Research (paid to institution): Merck

Faculty

Anthony L. Kovac, MD
Kasumi Arakawa Professor of Anesthesiology
University of Kansas Medical Center
Kansas City, KS

Disclosure: Speakers Bureau: Mundipharma
Contracted Research: Merck

Richard Pence, CRNA, MHA
Instructor in Anesthesiology, Mayo Clinic College of Medicine
Mayo Clinic
Jacksonville, FL

Disclosure: No relevant financial relationships to disclose.

Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose. 

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. Individuals have a relevant financial relationship if they have a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity contributes to the CME component of the American Board of Anesthesiology’s redesigned Maintenance of Certification in Anesthesiology™ (MOCA®) program, known as MOCA 2.0®. Please consult the ABA website, www.theABA.org, for a list of all MOCA 2.0 requirements.

This program has been prior approved by the American Association of Nurse Anesthetists for 1.00 Class A CE credits; Code Number 1040742; Expiration Date 6/29/2022.

AANA designates this program as meeting the criteria for up to 0.75 CE Credits in Pharmacology/Therapeutics.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, complete the posttest, learner assessment and program evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 80% of the posttest questions correctly. Only one (1) attempt to pass the posttest will be permitted. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate or an AANA Class A CE Credit Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Merck & Co., Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME/MOCA/AANA
1.0 AMA PRA Category 1 Credit(s)™ with ABA MOCA 2.0; AANA Class A CE Credit
Released: 6/30/2021
Expires: 6/29/2022
60 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for the activity is anesthesiologists, surgeons, nurse anesthetists, and other health care professionals involved in the management of patients undergoing anesthesia.

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

  • Review the benefits and limitations of current reversal agents.
  • Examine the best practices for the use of neuromuscular blocking agents, including the value of appropriate monitoring.
  • Assess the most recent evidence regarding the safety and efficacy of current and emerging therapies for the reversal of neuromuscular blocking agents.
  • Evaluate the significance of a multidisciplinary approach to manage surgical patients in need of deep neuromuscular blockade.

Activity Description

The introduction of neuromuscular blockade agents (NMBAs) revolutionized the field of anesthesia. However, termination of the effects of these agents remains elusive, and they still have the potential for significant adverse outcomes. The cholinesterase inhibitor drugs first used to reverse curare have traditionally been used for reversing all NMBAs, but due to the limitations of these agents and the complications of residual neuromuscular block, development of improved reversal agents has been underway. A new class of drugs, selective relaxant binding agents, may overcome the limitations of cholinesterase inhibitors and quickly reverse both shallow and deep levels of aminosteroid neuromuscular block. In this podcast series, expert faculty review the benefits and limitations of current and emerging reversal agents, best practices for monitoring patients undergoing neuromuscular blockade, and the importance of a multidisciplinary approach when managing patients in the surgical setting.

Agenda

Best Practices for Monitoring Neuromuscular Blockade with J. Ross Renew, MD, FASA, FASE, and Anthony L. Kovac, MD
Benefits and Drawbacks of Conventional Reversal Agents with J. Ross Renew, MD, FASA, FASE, and Richard Pence, CRNA, MHA
Current and Emerging NMB Therapies with  J. Ross Renew, MD, FASA, FASE, and Anthony L. Kovac, MD
Significance of a Multidisciplinary Approach for NMBAs with J. Ross Renew, MD, FASA, FASE, and Richard Pence, CRNA, MHA

Activity Chair

J. Ross Renew, MD, FASA, FASE
Assistant Professor of Anesthesiology
Mayo Clinic
Jacksonville, FL

Disclosure: Contracted Research (paid to institution): Merck

Faculty

Anthony L. Kovac, MD
Kasumi Arakawa Professor of Anesthesiology
University of Kansas Medical Center
Kansas City, KS

Disclosure: Speakers Bureau: Mundipharma
Contracted Research: Merck

Richard Pence, CRNA, MHA
Instructor in Anesthesiology, Mayo Clinic College of Medicine
Mayo Clinic
Jacksonville, FL

Disclosure: No relevant financial relationships to disclose.

Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose. 

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. Individuals have a relevant financial relationship if they have a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity contributes to the CME component of the American Board of Anesthesiology’s redesigned Maintenance of Certification in Anesthesiology™ (MOCA®) program, known as MOCA 2.0®. Please consult the ABA website, www.theABA.org, for a list of all MOCA 2.0 requirements.

This program has been prior approved by the American Association of Nurse Anesthetists for 1.00 Class A CE credits; Code Number 1040742; Expiration Date 6/29/2022.

AANA designates this program as meeting the criteria for up to 0.75 CE Credits in Pharmacology/Therapeutics.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, complete the posttest, learner assessment and program evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 80% of the posttest questions correctly. Only one (1) attempt to pass the posttest will be permitted. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate or an AANA Class A CE Credit Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Merck & Co., Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Surgery Presentations

1.00 AANA / CME / MOCA
Vindico
Neuromuscular Blockade Reversal: Navigating the Therapeutic Landscape to Achieve Optimal Patient Outcomes

Neuromuscular Blockade Reversal: Navigating the Therapeutic Landscape to Achieve Optimal Patient Outcomes

Start

Activity Details

Free CME/MOCA/AANA
1.0 AMA PRA Category 1 Credit(s)™ with ABA MOCA 2.0; AANA Class A CE Credit
Released: 6/30/2021
Expires: 6/29/2022
60 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for the activity is anesthesiologists, surgeons, nurse anesthetists, and other health care professionals involved in the management of patients undergoing anesthesia.

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

  • Review the benefits and limitations of current reversal agents.
  • Examine the best practices for the use of neuromuscular blocking agents, including the value of appropriate monitoring.
  • Assess the most recent evidence regarding the safety and efficacy of current and emerging therapies for the reversal of neuromuscular blocking agents.
  • Evaluate the significance of a multidisciplinary approach to manage surgical patients in need of deep neuromuscular blockade.

Activity Description

The introduction of neuromuscular blockade agents (NMBAs) revolutionized the field of anesthesia. However, termination of the effects of these agents remains elusive, and they still have the potential for significant adverse outcomes. The cholinesterase inhibitor drugs first used to reverse curare have traditionally been used for reversing all NMBAs, but due to the limitations of these agents and the complications of residual neuromuscular block, development of improved reversal agents has been underway. A new class of drugs, selective relaxant binding agents, may overcome the limitations of cholinesterase inhibitors and quickly reverse both shallow and deep levels of aminosteroid neuromuscular block. In this podcast series, expert faculty review the benefits and limitations of current and emerging reversal agents, best practices for monitoring patients undergoing neuromuscular blockade, and the importance of a multidisciplinary approach when managing patients in the surgical setting.

Agenda

Best Practices for Monitoring Neuromuscular Blockade with J. Ross Renew, MD, FASA, FASE, and Anthony L. Kovac, MD
Benefits and Drawbacks of Conventional Reversal Agents with J. Ross Renew, MD, FASA, FASE, and Richard Pence, CRNA, MHA
Current and Emerging NMB Therapies with  J. Ross Renew, MD, FASA, FASE, and Anthony L. Kovac, MD
Significance of a Multidisciplinary Approach for NMBAs with J. Ross Renew, MD, FASA, FASE, and Richard Pence, CRNA, MHA

Activity Chair

J. Ross Renew, MD, FASA, FASE
Assistant Professor of Anesthesiology
Mayo Clinic
Jacksonville, FL

Disclosure: Contracted Research (paid to institution): Merck

Faculty

Anthony L. Kovac, MD
Kasumi Arakawa Professor of Anesthesiology
University of Kansas Medical Center
Kansas City, KS

Disclosure: Speakers Bureau: Mundipharma
Contracted Research: Merck

Richard Pence, CRNA, MHA
Instructor in Anesthesiology, Mayo Clinic College of Medicine
Mayo Clinic
Jacksonville, FL

Disclosure: No relevant financial relationships to disclose.

Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose. 

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. Individuals have a relevant financial relationship if they have a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity contributes to the CME component of the American Board of Anesthesiology’s redesigned Maintenance of Certification in Anesthesiology™ (MOCA®) program, known as MOCA 2.0®. Please consult the ABA website, www.theABA.org, for a list of all MOCA 2.0 requirements.

This program has been prior approved by the American Association of Nurse Anesthetists for 1.00 Class A CE credits; Code Number 1040742; Expiration Date 6/29/2022.

AANA designates this program as meeting the criteria for up to 0.75 CE Credits in Pharmacology/Therapeutics.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, complete the posttest, learner assessment and program evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 80% of the posttest questions correctly. Only one (1) attempt to pass the posttest will be permitted. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate or an AANA Class A CE Credit Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Merck & Co., Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME/MOCA/AANA
1.0 AMA PRA Category 1 Credit(s)™ with ABA MOCA 2.0; AANA Class A CE Credit
Released: 6/30/2021
Expires: 6/29/2022
60 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for the activity is anesthesiologists, surgeons, nurse anesthetists, and other health care professionals involved in the management of patients undergoing anesthesia.

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

  • Review the benefits and limitations of current reversal agents.
  • Examine the best practices for the use of neuromuscular blocking agents, including the value of appropriate monitoring.
  • Assess the most recent evidence regarding the safety and efficacy of current and emerging therapies for the reversal of neuromuscular blocking agents.
  • Evaluate the significance of a multidisciplinary approach to manage surgical patients in need of deep neuromuscular blockade.

Activity Description

The introduction of neuromuscular blockade agents (NMBAs) revolutionized the field of anesthesia. However, termination of the effects of these agents remains elusive, and they still have the potential for significant adverse outcomes. The cholinesterase inhibitor drugs first used to reverse curare have traditionally been used for reversing all NMBAs, but due to the limitations of these agents and the complications of residual neuromuscular block, development of improved reversal agents has been underway. A new class of drugs, selective relaxant binding agents, may overcome the limitations of cholinesterase inhibitors and quickly reverse both shallow and deep levels of aminosteroid neuromuscular block. In this podcast series, expert faculty review the benefits and limitations of current and emerging reversal agents, best practices for monitoring patients undergoing neuromuscular blockade, and the importance of a multidisciplinary approach when managing patients in the surgical setting.

Agenda

Best Practices for Monitoring Neuromuscular Blockade with J. Ross Renew, MD, FASA, FASE, and Anthony L. Kovac, MD
Benefits and Drawbacks of Conventional Reversal Agents with J. Ross Renew, MD, FASA, FASE, and Richard Pence, CRNA, MHA
Current and Emerging NMB Therapies with  J. Ross Renew, MD, FASA, FASE, and Anthony L. Kovac, MD
Significance of a Multidisciplinary Approach for NMBAs with J. Ross Renew, MD, FASA, FASE, and Richard Pence, CRNA, MHA

Activity Chair

J. Ross Renew, MD, FASA, FASE
Assistant Professor of Anesthesiology
Mayo Clinic
Jacksonville, FL

Disclosure: Contracted Research (paid to institution): Merck

Faculty

Anthony L. Kovac, MD
Kasumi Arakawa Professor of Anesthesiology
University of Kansas Medical Center
Kansas City, KS

Disclosure: Speakers Bureau: Mundipharma
Contracted Research: Merck

Richard Pence, CRNA, MHA
Instructor in Anesthesiology, Mayo Clinic College of Medicine
Mayo Clinic
Jacksonville, FL

Disclosure: No relevant financial relationships to disclose.

Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose. 

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. Individuals have a relevant financial relationship if they have a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity contributes to the CME component of the American Board of Anesthesiology’s redesigned Maintenance of Certification in Anesthesiology™ (MOCA®) program, known as MOCA 2.0®. Please consult the ABA website, www.theABA.org, for a list of all MOCA 2.0 requirements.

This program has been prior approved by the American Association of Nurse Anesthetists for 1.00 Class A CE credits; Code Number 1040742; Expiration Date 6/29/2022.

AANA designates this program as meeting the criteria for up to 0.75 CE Credits in Pharmacology/Therapeutics.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, complete the posttest, learner assessment and program evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 80% of the posttest questions correctly. Only one (1) attempt to pass the posttest will be permitted. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate or an AANA Class A CE Credit Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Merck & Co., Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

0.50 CME
Vindico
Cytomegalovirus in the Transplantation Setting: Assessing the Evidence in Real-world Applications - A Game On! Challenge

Cytomegalovirus in the Transplantation Setting: Assessing the Evidence in Real-world Applications - A Game On! Challenge

Start

Activity Details

Free CME
0.50 AMA PRA Category 1 Credit(s)
Released: March 2, 2021
Expires: March 1, 2022
30 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is infectious disease specialists and other health care professionals involved in the management of patients with cytomegalovirus.

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Incorporate recent evidence into practice regarding the use of prophylactic and preemptive measures to prevent cytomegalovirus (CMV) disease in transplant recipients.
  • Differentiate conventional versus newer antiviral therapies in terms of safety and efficacy, ability to reduce CMV reactivation, and improvement of survival in transplant recipients.
  • Evaluate the optimal duration of prophylactic or preemptive treatment in patients at risk for CMV reactivation.

Activity Description

Cytomegalovirus (CMV) infection after solid organ and hematopoietic stem cell transplantation is one of the most critical infectious complications related to host immune recovery. Management of the virus is categorized into prophylactic, preemptive, and targeted treatment. Conventional anti-CMV therapies are associated with suboptimal efficacy, toxicity, and resistance. Newer antivirals may provide effective prevention as well as treatment of CMV disease without the safety concerns and drug resistance. In this continuing medical education activity, expert clinicians will discuss the latest on diagnosing and managing patients with CMV infection in the transplantation setting.

Faculty

Roy F. Chemaly, MD, MPH, FIDSA, FACP
Professor of Medicine
Director, Clinical Virology Research
Chief Infection Control Officer
Department of ID/IC/EH
University of Texas MD Anderson Cancer Center
Houston, TX

Disclosure:
Consulting Fee: Ansun BioPharma, Chimerix, Cidara, Janssen, Merck, Oxford Immunotec, ReViral, Takeda
Speakers Bureau: Merck
Contracted Research: AiCuris, Ansun BioPharma, Janssen, Karius, Merck, Takeda, Viracor

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, March 2, 2021 to March 1, 2022.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for the question. A satisfactory score is defined as answering 2 out of 3 of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Merck & Co., Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME
0.50 AMA PRA Category 1 Credit(s)
Released: March 2, 2021
Expires: March 1, 2022
30 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is infectious disease specialists and other health care professionals involved in the management of patients with cytomegalovirus.

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Incorporate recent evidence into practice regarding the use of prophylactic and preemptive measures to prevent cytomegalovirus (CMV) disease in transplant recipients.
  • Differentiate conventional versus newer antiviral therapies in terms of safety and efficacy, ability to reduce CMV reactivation, and improvement of survival in transplant recipients.
  • Evaluate the optimal duration of prophylactic or preemptive treatment in patients at risk for CMV reactivation.

Activity Description

Cytomegalovirus (CMV) infection after solid organ and hematopoietic stem cell transplantation is one of the most critical infectious complications related to host immune recovery. Management of the virus is categorized into prophylactic, preemptive, and targeted treatment. Conventional anti-CMV therapies are associated with suboptimal efficacy, toxicity, and resistance. Newer antivirals may provide effective prevention as well as treatment of CMV disease without the safety concerns and drug resistance. In this continuing medical education activity, expert clinicians will discuss the latest on diagnosing and managing patients with CMV infection in the transplantation setting.

Faculty

Roy F. Chemaly, MD, MPH, FIDSA, FACP
Professor of Medicine
Director, Clinical Virology Research
Chief Infection Control Officer
Department of ID/IC/EH
University of Texas MD Anderson Cancer Center
Houston, TX

Disclosure:
Consulting Fee: Ansun BioPharma, Chimerix, Cidara, Janssen, Merck, Oxford Immunotec, ReViral, Takeda
Speakers Bureau: Merck
Contracted Research: AiCuris, Ansun BioPharma, Janssen, Karius, Merck, Takeda, Viracor

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, March 2, 2021 to March 1, 2022.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for the question. A satisfactory score is defined as answering 2 out of 3 of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Merck & Co., Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com